Dabomb Protein Biotech (ROCO:6578) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Dabomb Protein Biotech EBITDA Margin % Related Terms
Dabomb Protein Biotech EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Dabomb Protein Biotech's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, Dabomb Protein Biotech's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dabomb Protein Biotech EBITDA Margin % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Dabomb Protein Biotech's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Dabomb Protein Biotech's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dabomb Protein Biotech (ROCO:6578) has a EBITDA Margin % of -42.34% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Dabomb Protein Biotech and its competitors. According to the industry distribution chart, Dabomb Protein Biotech ranks #1745 out of 1952 companies in the Consumer Packaged Goods industry, placing it in the top 89.4%.
Is Dabomb Protein Biotech's EBITDA Margin % too high?
Dabomb Protein Biotech's current EBITDA Margin % is -42.34%. Based on the distribution chart, Dabomb Protein Biotech ranks #1745 out of 1952 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Dabomb Protein Biotech has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Dabomb Protein Biotech's EBITDA Margin % compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Dabomb Protein Biotech ranks #1745 out of 1952 companies for EBITDA Margin %. This places Dabomb Protein Biotech in the lower half of its industry. The industry median EBITDA Margin % is 8.98. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Consumer Packaged Goods company?
The median EBITDA Margin % among Consumer Packaged Goods companies is 8.98, based on 1,952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Dabomb Protein Biotech and its competitors. For the Consumer Packaged Goods industry, the median EBITDA Margin % is 8.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dabomb Protein Biotech's current EBITDA Margin % is -42.34%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dabomb Protein Biotech stock overvalued right now?
Based on GuruFocus' analysis, Dabomb Protein Biotech (ROCO:6578) is currently considered Fairly Valued. The stock's GF Value™ is NT$14.62, compared to a current price of NT$16.10 — trading 10.1% above its estimated fair value. The current EBITDA Margin % is -42.34%. Dabomb Protein Biotech's overall GF Score™ is 61/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Dabomb Protein Biotech (ROCO:6578), the current EBITDA Margin % is -42.34% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dabomb Protein Biotech (ROCO:6578) Overvalued in 2026?
Based on GuruFocus' analysis, Dabomb Protein Biotech stock appears to be overvalued.
The current stock price of NT$16.10 is trading 10.1% above its estimated GF Value™ of NT$14.62.
GuruFocus considers Dabomb Protein Biotech to be Fairly Valued.
Key valuation signals for ROCO:6578:
EBITDA Margin %: -42.34%
GF Value™: NT$14.62 vs. price of NT$16.10 (10.1% above fair value)
No single metric tells the full story. See the ROCO:6578 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dabomb Protein Biotech Corp is engaged in the manufacture, wholesale, and sale of hydrolyzed soy protein. The products of the company include Plant protein, Antibiotics alternatives, Pet care, Core technology, and CDMO(ODM/OEM). The company operates in a single segment engaged in the manufacture, wholesale and sales of hydrolysed soy protein. Geographically it operates in Malaysia, Taiwan, USA, Vietnam, and Others with majority of the revenue deriving from Vietnam.
61GF Score
Get the complete analysis for ROCO:6578
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6578 has been successfully added to your 
